OBJECTIVES: Acute myeloid leukemia (AML) is classified in part by recurrent cytogenetic abnormalities, often detected by both fluorescent in situ hybridization (FISH) and karyotype. The goal of this study was to assess the utility of FISH and karyotyping at diagnosis and follow-up. METHODS: Adult AML samples at diagnosis or follow-up with karyotype and FISH were identified. Concordance was determined, and clinical characteristics and outcomes for discordant results were evaluated. RESULTS: Karyotype and FISH results were concordant in 193 (95.0%) of 203 diagnostic samples. In 10 cases, FISH detected an abnormality, but karyotype was normal. Of these, one had a FISH result with clinical significance. In follow-up cases, 17 (8.1%) of 211 showed FISH-positive discordant results; most were consistent with low-level residual disease. CONCLUSIONS: Clinically significant discordance between karyotype and AML FISH is uncommon. Consequently, FISH testing can safely be omitted from most of these samples. Focused FISH testing is more useful at follow-up, for minimal residual disease detection.
OBJECTIVES: Acute myeloid leukemia (AML) is classified in part by recurrent cytogenetic abnormalities, often detected by both fluorescent in situ hybridization (FISH) and karyotype. The goal of this study was to assess the utility of FISH and karyotyping at diagnosis and follow-up. METHODS: Adult AML samples at diagnosis or follow-up with karyotype and FISH were identified. Concordance was determined, and clinical characteristics and outcomes for discordant results were evaluated. RESULTS: Karyotype and FISH results were concordant in 193 (95.0%) of 203 diagnostic samples. In 10 cases, FISH detected an abnormality, but karyotype was normal. Of these, one had a FISH result with clinical significance. In follow-up cases, 17 (8.1%) of 211 showed FISH-positive discordant results; most were consistent with low-level residual disease. CONCLUSIONS: Clinically significant discordance between karyotype and AML FISH is uncommon. Consequently, FISH testing can safely be omitted from most of these samples. Focused FISH testing is more useful at follow-up, for minimal residual disease detection.
Authors: Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk Journal: N Engl J Med Date: 2016-06-09 Impact factor: 91.245
Authors: Adam C Seegmiller; Annette S Kim; Claudio A Mosse; Mia A Levy; Mary Ann Thompson; Megan K Kressin; Madan H Jagasia; Stephen A Strickland; Nishitha M Reddy; Edward R Marx; Kristy J Sinkfield; Herschel N Pollard; W Dale Plummer; William D Dupont; Edward K Shultz; Robert S Dittus; William W Stead; Samuel A Santoro; Mary M Zutter Journal: Am J Clin Pathol Date: 2013-11 Impact factor: 2.493
Authors: Said M H Abdou; Dalal M Jadayel; Toon Min; G John Swansbury; Melissa G Dainton; Osman Jafer; Ray L Powles; Daniel Catovsky Journal: Leuk Lymphoma Date: 2002-01
Authors: Margaret R O'Donnell; Camille N Abboud; Jessica Altman; Frederick R Appelbaum; Daniel A Arber; Eyal Attar; Uma Borate; Steven E Coutre; Lloyd E Damon; Salil Goorha; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Martin S Tallman; Eunice S Wang; Maoko Naganuma; Kristina M Gregory Journal: J Natl Compr Canc Netw Date: 2012-08 Impact factor: 11.908
Authors: M A Caligiuri; M P Strout; D Lawrence; D C Arthur; M R Baer; F Yu; S Knuutila; K Mrózek; A R Oberkircher; G Marcucci; A de la Chapelle; E Elonen; A W Block; P N Rao; G P Herzig; B L Powell; T Ruutu; C A Schiffer; C D Bloomfield Journal: Cancer Res Date: 1998-01-01 Impact factor: 12.701
Authors: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield Journal: Blood Date: 2009-04-08 Impact factor: 22.113
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: Adam C Seegmiller; Annette S Kim; Claudio A Mosse; Aaron C Shaver; Mary Ann Thompson; Shaoying Li; David R Head; Mary M Zutter Journal: Am J Clin Pathol Date: 2016-11-01 Impact factor: 2.493